Premium
In vitro susceptibility testing in fungi: a global perspective on a variety of methods
Author(s) -
LassFlörl Cornelia,
Perkhofer Susanne,
Mayr Astrid
Publication year - 2010
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2009.01813.x
Subject(s) - etest , antifungal , broth microdilution , agar , antifungal drugs , drug resistance , in vivo , aspergillus , caspofungin , biology , voriconazole , in vitro , microbiology and biotechnology , antifungal drug , medicine , antibiotics , minimum inhibitory concentration , bacteria , genetics , biochemistry
Summary Candida and Aspergillus species are the most common causes of invasive fungal infections in immunocompromised patients. The introduction of new antifungal agents and recent reports of resistance emerging during treatment have highlighted the need for in vitro susceptibility testing. For some drugs, there is a supporting in vitro – in vivo correlation available from studies of clinical efficacy. Both intrinsic and emergent antifungal drug resistance are encountered. Various testing procedures have been proposed, including macrodilution and microdilution, agar diffusion, disk diffusion and Etest. Early recognition of infections caused by pathogens that are resistant to one or more antifungals is highly warranted to optimise treatment and patient outcome.